IntelGenx Announces Definitive Agreement with Tilray® to Form an Exclusive, Worldwide Partnership for Cannabis-Infused VersaFilm™ Products
November 07, 2018 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Nov. 07, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced the execution of a definitive...
IntelGenx to Report Third Quarter 2018 Financial Results on November 8, 2018 – Conference Call to Follow
November 01, 2018 16:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Nov. 01, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) today announced that it will release its third quarter 2018 financial results...
The Spanish Agency of Medicines and Medical Devices Grants Marketing Authorization of RIZAPORT®
October 31, 2018 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Oct. 31, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announced that its commercialization partner for...
IntelGenx Completes US$12 Million Equity Offering
October 22, 2018 18:53 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Oct. 22, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announce that it has closed its...
IntelGenx Partner Insud Pharma Submits ANDA for Co-Developed Generic Buccal Film Product
October 04, 2018 08:16 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Oct. 04, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced that an Abbreviated New Drug Application (“ANDA”)...
Patient Recruitment to Commence in IntelGenx’s Phase 2a Montelukast VersaFilm™ Trial in Mild to Moderate Alzheimer’s Disease
September 25, 2018 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Sept. 25, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced that patient recruitment will commence for the...
IntelGenx to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
August 30, 2018 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Aug. 30, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) (the “Company” or “IntelGenx”) today announced that its Chief Financial Officer, Andre...
IntelGenx Reports Second Quarter 2018 Financial Results
August 09, 2018 16:17 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Aug. 09, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) (the “Company” or “IntelGenx”) today reported financial results for the second quarter...
IntelGenx to Report Second Quarter 2018 Financial Results on Aug 9, 2018 – Conference Call to Follow
August 02, 2018 16:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Aug. 02, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) today announced that it will release its second quarter 2018 financial results...
IntelGenx Receives CIPO Notice of Allowance for Loxapine VersaFilm™ Patent
July 05, 2018 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, July 05, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) (“IntelGenx” or the “Company”), a leading oral drug delivery company primarily focused on the...